Read on Twitter
I presented a poster at #NKFClinicals. This came from working with ViforCSL on the KALM-1 and KALM-2 meta-analysis of the pivotal trials of difelikefalin for CKD associated pruritus (CKDaP). About a year ago we brainstomed what other lessons could we could pull from the data. 
A question we had was how quickly do people respond to the drug, or put more practically, if you start a patient on difelikefalin and a month later they are still having intense itch, how likely will it be that they still could respond?
Look at the only figure on the poster and focus on the bars, this gives the fraction of people who will ultimately respond to difelikefalin who have responded at 4 weeeks, 8 weeks and 12 weeks.
About half of the people that ultimately had a meaningful reduction in itch (while on DFK) did so by 4 weeks. And that number moves up to 85% at 8 weeks.
So at one month, if the patient hasn't responded it is worth pushing on another month. But after 8 weeks there is little left
So at one month, if the patient hasn't responded it is worth pushing on another month. But after 8 weeks there is little left
The original meta-analysis of KALM-1 and KALM-2 can be found here: kidneymedicinejournal.org/article/S2590-…
The KALM-1 stand alone data is here: nejm.org/doi/full/10.10…
• • •
Missing some Tweet in this thread? You can try to
force a refresh
